GenRx Pty Ltd v Sanofi-Aventis [2007] FCA 1485

An interlocutory injunction should be granted to Sanofi-Aventis as the longstanding existence and exploitation of the patent, GenRx's delay in bringing revocation proceedings, and the potential for irreparable disruption to the status quo together support a prima facie case and tip the balance of convenience in favour of not permitting GenRx to enter the market pending trial.

Jurisdiction: Australia
Judgment Date: 21 September 2007
Procedural Posture: Patent Infringement and Revocation Proceedings / Interlocutory Application for Injunction
Outcome: Interlocutory injunction granted in favour of Sanofi-Aventis, proceeding stood over.
Legal Topics: ['interlocutory Injunction' 'patent Infringement' 'prima Facie Case' 'balance of Convenience' 'revocation of Patent']

['intellectual Property Law' 'patents'] ['interlocutory Injunction' 'patent Infringement' 'prima Facie Case' 'balance of Convenience' 'revocation of Patent']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1

Procedural Posture

Patent Infringement and Revocation Proceedings / Interlocutory Application for Injunction

Legal Issues

1 ['Whether interlocutory injunction should be granted to restrain infringement of a patent pending determination of revocation proceedings' 'Whether a prima facie case for injunction is established where validity of the patent is challenged' 'Whether balance of convenience favours granting the injunction']

Ratio Decidendi

Court Disposition

Interlocutory injunction granted in favour of Sanofi-Aventis, proceeding stood over.

Orders

['The proceeding stand over to 25 September 2007 at 9.30 am.']